Dr. Levine on Immunotherapy for Endometrial Cancer

Douglas A. Levine, MD
Published: Tuesday, Sep 19, 2017



Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Immunotherapy has capitalized on what was already known regarding endometrial cancer, states Levine.

Some microsatellite instability-high tumors are inherited through a defect in mismatch-repair genes, which is important for genetic screening. There is another link between inherited genetic events that are leading to effective treatments, states Levine.
 
SELECTED
LANGUAGE


Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Immunotherapy has capitalized on what was already known regarding endometrial cancer, states Levine.

Some microsatellite instability-high tumors are inherited through a defect in mismatch-repair genes, which is important for genetic screening. There is another link between inherited genetic events that are leading to effective treatments, states Levine.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Community Practice Connections™: Evolutions in the Treatment and Management of Advanced Cervical Cancer: Leveraging the Immunosuppressive Microenvironment, Addressing Ongoing Clinical NeedsJun 30, 20201.5
Publication Bottom Border
Border Publication
x